The abstract is read at the publisher; the summary is JClub's.
Daraxonrasib (RMC-6236) significantly reduced cell viability and inhibited tumor growth in RAS-mutant high-risk neuroblastoma models, with on-target MAPK suppression and survival extension in mice.
- Why it matters: Relapsed or refractory high-risk neuroblastoma has poor outcomes despite intensive multimodal therapy, and existing MEK or KRAS G12C inhibitors show limited preclinical single-agent activity.
- What they did: The study tested RMC-6236 across neuroblastoma models with RAS pathway activation, measuring effects on MAPK signaling, BIM induction, and cell death, then confirming on-target activity and tumor growth inhibition in RAS-mutant HRNB mouse models.
- The result: RMC-6236 increased BIM and promoted BIM:BCL-2 complexes in RAS-mutant neuroblastoma, and venetoclax further potentiated RMC-6236-mediated killing by disrupting these complexes.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.